With the SERNIVO Patient Savings Program, eligible patients can save on their SERNIVO Spray prescription
Eligible patients pay as little as $0. For more information, includinghow to request samples, sign up with the form below.
*Limitations apply. See eligibility rules for details.
SERNIVO is indicated for patients with mild-to-moderate plaque psoruasis, 18 years and older.
Enrolled patients had body surface area of involvment between 10% and 20%, and an Investigator’s Global Assessment (IGA) score of 3 (moderate)
Step 1: Shake the bottle
Remove the cap from the pump top.
Step 2: Push the pump
Hold the bottle upright. Point the opening of the pump top toward the affect area. To spray, push down on the pump top. NOTE: At first use, you may need to press the pump once or twice before SERNIVO can be sprayed.
Rub into skin
Spray only enough SERNIVO to cover the affected area.a Rub in gently. Replace the cap.
Adverse reactions and efficacy were assessed at Days 4, 8, 15 and 29. SERNIVO has been shown to be well-tolerated for patients to use for up to 4 weeks, as treatment duration in clinical trials did not extend beyond that time.
SERNIVO is the first oil-in-water emulsion (betamethasone dipropionate) delivered as a spray, making it a highly versatile topical. The patented SERNIVO formulation has been proven to penetrate and permeate skin layers.1,2
The active ingredient is betamethasone dipropionate. Other ingredients include butylated hydroxytoluene, cetostearyl alcohol, hydroxyethyl cellulose, methylparaben, mineral oil, oleyl alcohol, polyoxyl 20 cetostearyl ether, propylparaben, purified water, and sorbitan monostearate
aAvoid use on the face, scalp, axilla, groin, or other intertriginous areas.
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray.
Please refer to Full Prescribing Information.
SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.
To report ADVERSE EVENTS, call 1-800-399-2561 or AE@encorederm.com, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.